# Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

> **NCT05965505** · PHASE1 · TERMINATED · sponsor: **Axter Therapeutics (Beijing) Co., Ltd** · enrollment: 1 (actual)

## Conditions studied

- Relapsed or Refractory Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** AXT-1003

## Key facts

- **NCT ID:** NCT05965505
- **Lead sponsor:** Axter Therapeutics (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-11
- **Primary completion:** 2023-09-05
- **Final completion:** 2023-09-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to the adjustment of the protocol and expansion of the indication population, a new clinical trial protocol was submitted to the Health Authority, so the registration was conducted as a new clinical trial and this trial was terminated.
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05965505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05965505, "Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05965505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*